Qualigen Therapeutics, Inc.
QLGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $5,205 | $4,984 | $5,654 |
| % Growth | -100% | 4.4% | -11.9% | – |
| Cost of Goods Sold | $0 | $5,209 | $4,303 | $4,332 |
| Gross Profit | $0 | -$4 | $681 | $1,321 |
| % Margin | – | -0.1% | 13.7% | 23.4% |
| R&D Expenses | $1,197 | $5,209 | $6,837 | $11,717 |
| G&A Expenses | $4,205 | $6,096 | $10,836 | $11,725 |
| SG&A Expenses | $4,205 | $6,091 | $11,786 | $12,268 |
| Sales & Mktg Exp. | $0 | -$4 | $950 | $543 |
| Other Operating Expenses | $360 | -$5,209 | $1 | $5 |
| Operating Expenses | $5,762 | $6,096 | $18,623 | $23,984 |
| Operating Income | -$5,762 | -$11,305 | -$17,942 | -$22,663 |
| % Margin | – | -217.2% | -360% | -400.9% |
| Other Income/Exp. Net | -$391 | -$1,175 | $873 | $4,771 |
| Pre-Tax Income | -$6,153 | -$12,480 | -$21,300 | -$17,892 |
| Tax Expense | $6 | -$5 | -$265 | $5 |
| Net Income | -$6,159 | -$13,417 | -$21,035 | -$17,897 |
| % Margin | – | -257.8% | -422.1% | -316.6% |
| EPS | -17.28 | -2.46 | -5.48 | -6.1 |
| % Growth | -602.4% | 55.1% | 10.2% | – |
| EPS Diluted | -17.28 | -2.46 | -5.48 | -6.1 |
| Weighted Avg Shares Out | 362 | 5,071 | 3,838 | 2,933 |
| Weighted Avg Shares Out Dil | 362 | 5,073 | 3,840 | 2,933 |
| Supplemental Information | – | – | – | – |
| Interest Income | $129 | $0 | $0 | $43 |
| Interest Expense | $909 | $1,525 | $34 | $0 |
| Depreciation & Amortization | $0 | $4 | $12 | $322 |
| EBITDA | -$5,244 | -$11,300 | -$13,841 | -$22,341 |
| % Margin | – | -217.1% | -277.7% | -395.2% |